¼¼°èÀÇ Ä¡¿ Ä¡·á ½ÃÀå : Ä¡·á À¯Çüº°, Åõ¿© °æ·Îº°, À¯Åë ä³Îº°, Áö¿ªº°
Anal Fissure Treatment Market, By Treatment Type, By Route of Administration, By Distribution Channel, By Geography
»óǰÄÚµå
:
1741496
¸®¼Ä¡»ç
:
Coherent Market Insights
¹ßÇàÀÏ
:
2025³â 03¿ù
ÆäÀÌÁö Á¤º¸
:
¿µ¹®
¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
»ùÇà ¿äû ¸ñ·Ï¿¡ Ãß°¡
Ä¡¿ Ä¡·á ½ÃÀåÀº 2025³â 11¾ï 5,210¸¸ ´Þ·¯, 2032³â¿¡´Â 16¾ï 5,380¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, 2025-2032³â ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)Àº 5.3%¸¦ ³ªÅ¸³¾ Àü¸ÁÀÔ´Ï´Ù.
º¸°í¼ ¹üÀ§
º¸°í¼ »ó¼¼
±âÁØ ¿¬µµ
2024
2025³â ½ÃÀå ±Ô¸ð
11¾ï 5,210¸¸ ´Þ·¯
½ÇÀû µ¥ÀÌÅÍ
2020-2024³â
¿¹Ãø ±â°£
2025-2032³â
¿¹Ãø ±â°£(2025-2032³â) CAGR
5.30%
2032³â °¡Ä¡ ¿¹Ãø
16¾ï 5,380¸¸ ´Þ·¯
Ä¡¿Àº Àü ¼¼°èÀûÀ¸·Î ¸¹Àº »ç¶÷µéÀÌ ¾Î°í ÀÖ´Â ÈçÇÑ ÁúȯÀÔ´Ï´Ù. Ç×¹® Á¡¸·¿¡ ÀÛÀº Âõ¾îÁüÀ̳ª »óó°¡ »ý°Ü ¹èº¯ ½Ã ºÒÆíÇÔ°ú ÅëÁõ, ¶§·Î´Â ÃâÇ÷À» µ¿¹ÝÇÕ´Ï´Ù. Ä¡¿Àº ÀÚ¿¬ Ä¡À¯µÇ´Â °æ¿ìµµ ÀÖÁö¸¸, Áõ»óÀ» ¿ÏÈÇϰí Ä¡À¯¸¦ ÃËÁøÇϱâ À§ÇØ Ä¡·á°¡ ÇÊ¿äÇÑ °æ¿ìµµ ¸¹½À´Ï´Ù.
´ëºÎºÐÀÇ Ä¡¿Àº ¸î ÁÖ ¾È¿¡ ÀÚ¿¬ Ä¡À¯µÇÁö¸¸, Ä¡À¯µÇÁö ¾Ê´Â °æ¿ì ÇÕº´ÁõÀ» À¯¹ßÇÒ ¼ö ÀÖ½À´Ï´Ù. À̸¦ ¸¸¼º Ä¡¿À̶ó°í ÇÕ´Ï´Ù. Ä¡¿Àº Ä¡À¯µÇÁö ¾Ê°í ¾Ç¼øÈ¯À» ¹Ýº¹Çϸç ÈäÅͰ¡ °è¼Ó ³²°Ô µË´Ï´Ù.
Ä¡¿ÀÇ Áõ»óÀ¸·Î´Â ¹èº¯ ½Ã ÅëÁõ, ¹èº¯ ÈÄ ¸î ½Ã°£ µ¿¾È Áö¼ÓµÇ´Â ÅëÁõ, ¹èº¯ ÈÄ ´ëº¯À̳ª ÈÀåÁö¿¡ ¼±¸íÇÑ ºÓÀº Çǰ¡ ¹¯¾î³ª¿À´Â °æ¿ì, Ç×¹® ÁÖº¯ ÇǺο¡ ´«¿¡ º¸ÀÌ´Â ±Õ¿ÀÌ »ý±â´Â °æ¿ì, Ä¡¿ ÁÖº¯ ÇǺο¡ ÀÛÀº µ¢¾î¸®°¡ »ý±â°Å³ª ÇǺΰ¡ ¹þ°ÜÁö´Â °æ¿ì µîÀÌ ÀÖ½À´Ï´Ù.
¼¼°è Ä¡¿ Ä¡·á ½ÃÀåÀº Àü ¼¼°è Ä¡¿ À¯º´·ü Áõ°¡·Î ÀÎÇØ °ý¸ñÇÒ ¸¸ÇÑ ¼ºÀåÀ» º¸À̰í ÀÖ½À´Ï´Ù. ÁÂ½Ä »ýȰ½À°ü, ½Ä½À°ü º¯È, °í·ÉÈ Àα¸ Áõ°¡ µîÀÇ ¿äÀÎÀÌ Ä¡¿ ¹ß»ý·ü Áõ°¡¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ´Ù¾çÇÑ Ä¡·á ¿É¼ÇÀÇ °¡¿ë¼º¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö°í ÃÖ¼Ò Ä§½ÀÀû ½Ã¼ú¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÏ¸é¼ ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù.
½ÃÀå ¿ªÇÐ:
¼¼°èÀûÀ¸·Î Ä¡¿ÀÇ À¯º´·ü Áõ°¡¿Í ½ÃÀå ÁøÃâ±â¾÷ÀÇ Á¦Ç° Ãâ½Ã Áõ°¡´Â ¿¹Ãø ±â°£ µ¿¾È ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¿¹¸¦ µé¾î, 2022³â 9¿ù 15ÀÏ Clinical MedicineÀÌ ¹ßÇ¥ÇÑ ÀÚ·á¿¡ µû¸£¸é, ´º¸ß½ÃÄÚ ÁÖ¿¡¼ ÀÏ¹Ý Àα¸ÀÇ ¿¬°£ Ä¡¿ ¹ß»ý·üÀº 0.11%ÀÔ´Ï´Ù.
º» Á¶»çÀÇ ÁÖ¿ä Æ¯Â¡
ÀÌ º¸°í¼´Â 2024³âÀ» ±âÁØ ¿¬µµ, 2025-2032³âÀÇ ¿¹Ãø ±â°£ µ¿¾È ½ÃÀå ±Ô¸ð¿Í ¿¬Æò±Õ ¼ºÀå·ü(CAGR%)À» Æ÷ÇÔÇÑ ¼¼°è Ä¡¿ Ä¡·á ½ÃÀåÀ» Á¾ÇÕÀûÀ¸·Î ºÐ¼®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
ÀÌ º¸°í¼´Â ´Ù¾çÇÑ ºÎ¹®¿¡ °ÉÄ£ ÀáÀçÀû ¼öÀÍ ±âȸ¸¦ ÆÄ¾ÇÇϰí ÀÌ ½ÃÀå¿¡ ´ëÇÑ ¸Å·ÂÀûÀÎ ÅõÀÚ Á¦¾È ¸ÅÆ®¸¯½º¸¦ Á¦°øÇÕ´Ï´Ù.
½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ, ¾ïÁ¦¿äÀÎ, ±âȸ, ½ÅÁ¦Ç° Ãâ½Ã ¹× ½ÂÀÎ, ½ÃÀå µ¿Çâ, Áö¿ªº° Àü¸Á, ÁÖ¿ä ±â¾÷ÀÇ °æÀï Àü·« µî¿¡ ´ëÇÑ Áß¿äÇÑ °íÂûÀ» Á¦°øÇÕ´Ï´Ù.
¼¼°è Ä¡¿ Ä¡·á ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷ ÇÁ·ÎÆÄÀÏ, ±â¾÷ ¹è°æ, Á¦Ç° Æ÷Æ®Æú¸®¿À, À繫 ½ÇÀû, Àü·« µîÀ» ¼Ò°³ÇÕ´Ï´Ù.
ÀÌ º¸°í¼ÀÇ ÅëÂû·ÂÀ» ÅëÇØ ±â¾÷ÀÇ ¸¶ÄÉÆÃ ´ã´çÀÚ¿Í °æ¿µÁøÀº Á¦Ç° Ãâ½Ã, ½ÃÀå È®´ë, ¸¶ÄÉÆÃ Àü¼ú¿¡ ´ëÇÑ Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù.
Ä¡¿ Ä¡·á ¼¼°è ½ÃÀå º¸°í¼´Â ÅõÀÚÀÚ, °ø±Þ¾÷ü, Á¦Ç° Á¦Á¶¾÷ü, À¯Åë¾÷ü, ½Å±Ô ½ÃÀå ÁøÃâ±â¾÷, À繫 ºÐ¼®°¡ µî ¾÷°èÀÇ ´Ù¾çÇÑ ÀÌÇØ°ü°èÀÚ¸¦ ´ë»óÀ¸·Î ÇÕ´Ï´Ù.
ÀÌÇØ°ü°èÀÚµéÀº ¼¼°è Ä¡¿ Ä¡·á ½ÃÀå ºÐ¼®¿¡ »ç¿ëµÇ´Â ´Ù¾çÇÑ Àü·« ¸ÅÆ®¸¯½º¸¦ ÅëÇØ Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù.
¸ñÂ÷
Á¦1Àå Á¶»ç ¸ñÀû°ú ÀüÁ¦Á¶°Ç
Á¦2Àå ½ÃÀå Àü¸Á
º¸°í¼ ¼³¸í
ÁÖ¿ä ¿ä¾à
Coherent Opportunity Map(COM)
Á¦3Àå ½ÃÀå ¿ªÇÐ, ±ÔÁ¦, µ¿Ç⠺м®
½ÃÀå ¿ªÇÐ
¿µÇ⠺м®
ÁÖ¿ä ÇÏÀ̶óÀÌÆ®
±ÔÁ¦ ½Ã³ª¸®¿À
Á¦Ç° ¹ß¸Å ¹× ½ÂÀÎ
PEST ºÐ¼®
PORTER ºÐ¼®
ÀμöÇÕº´(M&A) ½Ã³ª¸®¿À
Á¦4Àå ¼¼°èÀÇ Ä¡¿ Ä¡·á ½ÃÀå - Äڷγª¹ÙÀÌ·¯½º(COVID-19) ÆÒµ¥¹ÍÀÇ ¿µÇâ
COVID-19 ¿ªÇÐ
°ø±ÞÃø°ú ¼ö¿äÃø ºÐ¼®
°æÁ¦¿¡ ´ëÇÑ ¿µÇâ
Á¦5Àå ¼¼°èÀÇ Ä¡¿ Ä¡·á ½ÃÀå, Ä¡·á À¯Çüº°, 2020³â-2032³â
¼³»ç¾à
±¹¼Ò Áú»ê¿°
Ä®½· ±æÇ×Á¦
´ëº¯ ¿¬ÈÁ¦
¼ö¼ú
±âŸ
Á¦6Àå ¼¼°èÀÇ Ä¡¿ Ä¡·á ½ÃÀå, Åõ¿© °æ·Îº°, 2020³â-2032³â
Á¦7Àå ¼¼°èÀÇ Ä¡¿ Ä¡·á ½ÃÀå, À¯Åë ä³Îº°, 2020³â-2032³â
º´¿ø ¾à±¹
¼Ò¸Å ¾à±¹
¿Â¶óÀÎ ¾à±¹
Á¦8Àå ¼¼°èÀÇ Ä¡¿ Ä¡·á ½ÃÀå, Áö¿ªº°, 2020³â-2032³â
ºÏ¹Ì
À¯·´
¿µ±¹
µ¶ÀÏ
ÇÁ¶û½º
ÀÌÅ»¸®¾Æ
½ºÆäÀÎ
·¯½Ã¾Æ
±âŸ À¯·´
¾Æ½Ã¾ÆÅÂÆò¾ç
Áß±¹
ÀϺ»
Àεµ
È£ÁÖ
Çѱ¹
ASEAN
±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
¶óƾ¾Æ¸Þ¸®Ä«
ºê¶óÁú
¸ß½ÃÄÚ
¾Æ¸£ÇîÆ¼³ª
±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
秵¾ÆÇÁ¸®Ä«
³²¾ÆÇÁ¸®Ä«
ºÏ¾ÆÇÁ¸®Ä«
Áß¾Ó¾ÆÇÁ¸®Ä«
Á¦9Àå °æÀï ±¸µµ
Abbvie
Novartis AG
Teva Pharmaceuticals
Troikaa
RDD Pharma, Ltd
Kyowa Kirin Co., Ltd
Cipla Inc.
Ipsen Pharma
Sanofi
Boehringer Ingelheim International GmbH
Bliss GVS
SRS Life Sciences
Healthy Life Pharma Private Limited
Geri-Care Pharmaceuticals Corp
Á¦10Àå ¼½¼Ç
LSH
¿µ¹® ¸ñÂ÷
Anal Fissure Treatment Market is estimated to be valued at USD 1,152.1 Mn in 2025 and is expected to reach USD 1,653.8 Mn by 2032, growing at a compound annual growth rate (CAGR) of 5.3% from 2025 to 2032.
Report Coverage
Report Details
Base Year:
2024
Market Size in 2025:
USD 1,152.1 Mn
Historical Data for:
2020 To 2024
Forecast Period:
2025 To 2032
Forecast Period 2025 to 2032 CAGR:
5.30%
2032 Value Projection:
USD 1,653.8 Mn
Anal fissure is a common medical condition that affects a significant number of individuals worldwide. It refers to a small tear or cut in the lining of the anus, resulting in discomfort, pain, and sometimes bleeding during bowel movements. While anal fissures can heal on their own, it often require treatment to alleviate symptoms and promote healing.
Many anal fissures heal by themselves in a few weeks, but complications can develop when they don't. These are called chronic anal fissures. Instead of healing, they continue to reinforce themselves in a vicious cycle, leaving a persistent wound.
Symptoms of anal fissure includes; Pain during bowel movements, Pain after bowel movements that can last up to several hours, Bright red blood on the stool or toilet paper after a bowel movement, a visible crack in the skin around the anus, a small lump or skin tag on the skin near the anal fissure
Global anal fissure treatment market is witnessing significant growth due to increasing prevalence of anal fissures globally. Factors such as sedentary lifestyles, poor dietary habits, and rising aging population contribute to growing incidence of anal fissures. Rising awareness about the availability of various treatment options and increasing demand for minimally invasive procedures are further driving the market growth.
Market Dynamics:
Increasing prevalence of anal fissure globally and increasing product launches by the market players are expected to aid drive the market growth over the forecast period. For instance, on September 15, 2022, according to the data published by the Clinical Medicine, annual incidence of anal fissures in the general population is 0.11% in New Mexico.
Key Features of the Study:
This study provides a comprehensive analysis of the global anal fissure treatment market, including market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period of 2025-2032, with 2024 as the base year
The report elucidates potential revenue opportunities across different segments and offers attractive investment proposition matrices for this market
It provides key insights into market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
The profiles of key players in the global anal fissure treatment market are included, highlighting their company background, product portfolio, financial performance, and strategies
Key companies covered in this study include Abvie, Novartis AG, Teva Pharmaceuticals, Troikaa, RDD Pharma, Ltd, Kyowa Kirin Co., Ltd, Cipla Inc., Ipsen Pharma, Sanofi, Boehringer Ingelheim International GmbH, Bliss GVS, SRS Life Sciences, Healthy Life Pharma Private Limited, and Geri-Care Pharmaceuticals Corp
The insights from this report enable marketers and management authorities of companies to make informed decisions regarding product launches, market expansion, and marketing tactics
Global anal fissure treatment market report caters to various stakeholders in the industry, including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders can make informed decisions through different strategy matrices used in analyzing the global anal fissure treatment market
Anal Fissure Treatment Market Detailed Segmentation:
By Treatment Type
Laxatives
Topical Nitrates
Calcium Channel Blockers
Stool Softeners
Surgery
Others
By Route of Administration
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region:
North America
Europe
Asia Pacific
Latin America
Middle East
Africa
Company Profiles
Abvie
Novartis AG
Teva Pharmaceuticals
Troikaa
RDD Pharma, Ltd
Kyowa Kirin Co., Ltd
Cipla Inc.
Ipsen Pharma
Sanofi
Boehringer Ingelheim International GmbH.
Bliss GVS
SRS Life Sciences
Healthy Life Pharma Private Limited
Geri-Care Pharmaceuticals Corp.
Table of Contents
1. Research Objectives and Assumptions
Research Objectives
Assumptions
Abbreviations
2. Market Purview
Report Description
Market Definition and Scope
Executive Summary
Anal Fissure Treatment Market, By Treatment Type
Anal Fissure Treatment Market, By Route of Administration
Anal Fissure Treatment Market, By Distribution Channel
Anal Fissure Treatment Market, By Region
Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
Market Dynamics
Increasing Prevalence of Anal Fissures
Rising Awareness and Removing Social Stigma
Social Taboo Inhibiting Treatment Seeking
Product Recall
Huge Scope in Emerging Economies
Growing Demand for Minimally Invasive Procedures
Impact Analysis
Key Highlights
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario
4. Global Anal Fissure Treatment Market - Impact of Coronavirus (COVID-19) Pandemic
COVID-19 Epidemiology
Supply Side and Demand Side Analysis
Economic Impact
5. Global Anal Fissure Treatment Market, By Treatment Type, 2020-2032, (US$ Mn)
Introduction
Market Share Analysis, 2025 and 2032 (%)
Y-o-Y Growth Analysis, 2021 - 2032
Segment Trends
Laxatives
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
Topical Nitrates
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
Calcium Channel Blockers
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
Stool Softeners
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
Surgery
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Mn)
Others
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
6. Global Anal Fissure Treatment Market, By Route of Administration, 2020-2032, (US$ Mn)
Introduction
Market Share Analysis, 2025 and 2032 (%)
Y-o-Y Growth Analysis, 2021- 2032
Segment Trends
Oral
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
Topical
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
Others
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
7. Global Anal Fissure Treatment Market, By Distribution Channel, 2020-2032, (US$ Mn)
Introduction
Market Share Analysis, 2025 and 2032 (%)
Y-o-Y Growth Analysis, 2021- 2032
Segment Trends
Hospital Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
Retail Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
Online Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
8. Global Anal Fissure Treatment Market, By Region, 2020-2032, (US$ Mn)
Introduction
Market Share Analysis, By Region, 2025 and 2032 (%)
Y-o-Y Growth Analysis, For Region, 2021-2032
Country Trends
North America
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020-2032, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Mn)
Europe
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020-2032, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Mn)
U.K.
Germany
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020-2032, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Mn)
China
Japan
India
Australia
South Korea
ASEAN
Rest of Asia Pacific
Latin America
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020-2032, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Mn)
Brazil
Mexico
Argentina
Rest of Latin America
Middle East
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020-2032, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Mn)
GCC
Israel
Rest of Middle East
Africa
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020-2032, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020-2032, (US$ Mn)
South Africa
North Africa
Central Africa
9. Competitive Landscape
Abbvie
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Novartis AG
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
Teva Pharmaceuticals
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
Troikaa
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
RDD Pharma, Ltd
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
Kyowa Kirin Co., Ltd
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
Cipla Inc.
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
Ipsen Pharma
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
Sanofi
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
Boehringer Ingelheim International GmbH
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
Bliss GVS
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
SRS Life Sciences
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
Healthy Life Pharma Private Limited
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
Geri-Care Pharmaceuticals Corp
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
Analyst Views
10. Section
Research Methodology
About us
°ü·ÃÀÚ·á